… QR-313 was granted ODD in the U.S. and Europe. Axiomer ® RNA-editing technology was introduced at the Company’s second … QR-313 ready for clinical trials and validating our novel RNA-editing technology, Axiomer ® ,” said Daniel A. de Boer, … to future milestones and royalties. Axiomer ® RNA editing technology platform In June, ProQR introduced its …
… November 20 at 1:20-2:00 p.m. GMT Presentation at the 1 st RNA Editing Summit During the 1 st RNA Editing Summit to be held on November 19-20, 2019 in … and Development of ProQR. Presentation Title: Translating RNA Editing to Our Clinical Development Pipelines …
… advisory board. "Dr. Yu is a pioneer of targeted RNA editing to correct protein translation defects caused by … of therapies for rare genetic diseases based on novel RNA editing technologies including our Axiomer ® technology." … focuses on understanding the role of post-transcriptional RNA editing in regulating cellular processes, such as …
… highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens financial position … highlight clinical stage pipeline programs and Axiomer ® RNA editing platform LEIDEN, Netherlands & CAMBRIDGE, Mass., … partnership we entered into with Lilly around our Axiomer RNA base-editing platform and the appointment of Theresa …
… into a research collaboration to apply the Axiomer ® RNA editing technology to fibrosis targets selected by … loss associated with Usher syndrome type 2A. ADAR A-to-I RNA editing expert Dr. Peter A. Beal was appointed to ProQR’s … of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field of ADAR and A-to-I …
… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple therapeutic areas … ProQR is accelerating the development of its Axiomer RNA editing platform and pipeline activities and plans to …
ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR’s AI-enabled drug discovery for Axiomer™ProQR establishes AI Advisory Board with leaders from industry and academiaProQR’s first AI-discovered Development
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome